Plasma levels of olanzapine: Findings from an open-label study of adolescents and young adults with schizophrenia

被引：0
|
作者：
Dittmann, R [1 ]
Clement, H [1 ]
Knebel, W [1 ]
Roesch, F [1 ]
Hagenah, U [1 ]
Junghanss, J [1 ]
Maestele, A [1 ]
Mehler, C [1 ]
Meyer, C [1 ]
Pitzer, M [1 ]
Remschmidt, H [1 ]
Schlamp, D [1 ]
Schulte-Markwort, M [1 ]
Weiffenbach, O [1 ]
机构：
[1] Lilly Deutschland GmbH, Dept Med, Bad Homburg, Germany
来源：
SCHIZOPHRENIA BULLETIN | 2005年 / 31卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：481 / 481
页数：1
相关论文
共 50 条
  • [21] Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: An open-label, prospective trial
    Lindenmayer, JP
    Volavka, J
    Lieberman, J
    Sheitman, B
    Citrome, L
    Chakos, M
    Czobor, P
    Parker, B
    Iskander, A
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2001, 21 (04) : 448 - 453
  • [22] AN OPEN-LABEL STUDY OF FAMOTIDINE AS A TREATMENT FOR SCHIZOPHRENIA
    WHITEFORD, HA
    STEDMAN, TJ
    MCGRATH, JJ
    WELHAM, J
    POND, S
    JOURNAL OF PSYCHIATRY & NEUROSCIENCE, 1995, 20 (03): : 239 - 240
  • [23] Switching forensic schizophrenia outpatients from long-acting injectable antipsychotics to olanzapine: An open-label naturalistic study
    Bourget, D
    Labelle, A
    Boulay, LJ
    Tessier, P
    Ellis, J
    SCHIZOPHRENIA RESEARCH, 2004, 67 (01) : 160 - 161
  • [24] Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: Results from a 3-month prospective open-label study
    Wampers, Martien
    Hanssens, Linda
    van Winkel, Ruud
    Heald, Adrian
    Collette, Julien
    Peuskens, Joseph
    Reginster, Jean Yves
    Scheen, Andre
    De Hert, Marc
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 (01) : 17 - 26
  • [25] Open-label study of olanzapine in children with pervasive developmental disorder
    Kemner, C
    Willemsen-Swinkels, SHN
    de Jonge, M
    Tuynman-Qua, H
    van Engeland, H
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2002, 22 (05) : 455 - 460
  • [26] THE OPTIMISE STUDY: AMISULPRIDE AND OLANZAPINE FOLLOWED BY OPEN-LABEL TREATMENT WITH CLOZAPINE IN FIRST-EPISODE SCHIZOPHRENIA
    Arango, Celso
    SCHIZOPHRENIA BULLETIN, 2019, 45 : S115 - S115
  • [27] Olanzapine treatment in chronic drug-resistant childhood-onset schizophrenia: An open-label study
    Mozes, T
    Greenberg, Y
    Spivak, B
    Tyano, S
    Weizman, A
    Mester, R
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2003, 13 (03) : 311 - 317
  • [28] Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: Results of an open-label multicenter study in Japan
    Ishigooka, J
    Murasaki, M
    Miura, S
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2001, 55 (04) : 353 - 363
  • [29] Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: An open-label switch study
    Lindenmayer, JP
    Czobor, P
    Volavka, J
    Lieberman, JA
    Citrome, L
    Sheitman, B
    Chakos, M
    McEvoy, JP
    JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (10) : 931 - 935
  • [30] Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: Analysis of a randomized, open-label study
    Byerly, Matthew J.
    Marcus, Ronald N.
    Tran, Quynh-Van
    Eudicone, James M.
    Whitehead, Richard
    Baker, Ross A.
    SCHIZOPHRENIA RESEARCH, 2009, 107 (2-3) : 218 - 222
12345